Inpatient Neurology Consultations During the Onset of the SARS-CoV-2 New York City Pandemic: A Single Center Case Series

Radmard, Sara; Epstein, Susan L.; Roeder, Hannah; Michalak, Andrew J.; Shapiro, Steven D.; Boehme, Amelia K; Wilson, Tommy J.; Durán, Juan Carlos; Bain, Jennifer; Willey, Joshua Z.; Thakur, Kiran T.

doi:10.3389/fneur.2020.00805

Cited by 22 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the other studies identified in our review concerned COVID‐19 in adults 12,17,20 . Radmard et al 21 discussed neurological complications after COVID‐19 and presented data on 33 patients. There was only one paediatric patient under the age of 18 and that individual was 17 years of age.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19

2020

View full text Add to dashboard Cite

Aim Persistent symptoms in adults after COVID‐19 are emerging and the term long COVID is increasingly appearing in the literature. However, paediatric data are scarce. Methods This paper contains a case report of five Swedish children and the long‐term symptoms reported by their parents. It also includes a systematic literature review of the MEDLINE, EMBASE and Web of Science databases and the medRxiv/bioRxiv pre‐print servers up to 2 November 2020. Results The five children with potential long COVID had a median age of 12 years (range 9–15) and four were girls. They had symptoms for 6–8 months after their clinical diagnoses of COVID‐19. None were hospitalised at diagnosis, but one was later admitted for peri‐myocarditis. All five children had fatigue, dyspnoea, heart palpitations or chest pain, and four had headaches, difficulties concentrating, muscle weakness, dizziness and sore throats. Some had improved after 6–8 months, but they all suffered from fatigue and none had fully returned to school. The systematic review identified 179 publications and 19 of these were deemed relevant and read in detail. None contained any information on long COVID in children. Conclusion Children may experience similar long COVID symptoms to adults and females may be more affected.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The author read 19 in detail after screening the titles and abstracts. Of these, 11 were from MEDLINE, [10][11][12][13][14][15][16][17][18][19][20] two from EMBASE, 21,22 five from Web of Science [23][24][25][26][27] and one from medRxiv/bioRxiv. 28 There was no pre-specified protocol prior to the review.…”

Section: Systematic Literature Searchmentioning

confidence: 99%

Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19

2020

View full text Add to dashboard Cite

show abstract

“…The development of an epilepsy electronic patient portal may promote improved patient-clinician partnerships and facilitate patient self-management [23] 1.2. Seizure-related papers (Table 3): While one retrospective study reported no seizures in 304 patients with COVID-19 [25], multiple studies refuted that finding [24,[26][27][28][29]. Furthermore, many cases with new-onset focal seizures, serial seizures, and status epilepticus have been reported in the literature [30-49, 51, 63].…”

Section: Resultsmentioning

confidence: 99%

“…Another important issue is the occurrence of new-onset seizures in people with COVID-19. While seizure is not a common manifestation of COVID-19, it may happen in a variety of forms (e.g., focal motor, tonic-clonic, convulsive status epilepticus, and nonconvulsive status epilepticus) [28,[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47]. On the other hand, many patients with severe COVID-19 may have changes in their mental status [26,27].…”

Section: Discussionmentioning

confidence: 99%

COVID-19, de novo seizures, and epilepsy: a systematic review

et al. 2020

View full text Add to dashboard Cite

Objective We discuss the evidence on the occurrence of de novo seizures in patients with COVID-19, the consequences of this catastrophic disease in people with epilepsy (PWE), and the electroencephalographic (EEG) findings in patients with COVID-19. Methods This systematic review was prepared according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. MEDLINE, Scopus, and Embase from inception to August 15, 2020 were systematically searched. These key words were used: "COVID" AND "seizure" OR "epilepsy" OR "EEG" OR "status epilepticus" OR "electroencephalography". Results We could identify 62 related manuscripts. Many studies were case reports or case series of patients with COVID-19 and seizures. PWE showed more psychological distress than healthy controls. Many cases with new-onset focal seizures, serial seizures, and status epilepticus have been reported in the literature. EEG studies have been significantly ignored and underused globally. Conclusion Many PWE perceived significant disruption in the quality of care to them, and some people reported increase in their seizure frequency since the onset of the pandemic. Telemedicine is a helpful technology that may improve access to the needed care for PWE in these difficult times. De novo seizures may occur in people with COVID-19 and they may happen in a variety of forms. In addition to prolonged EEG monitoring, performing a through metabolic investigation, electrocardiogram, brain imaging, and a careful review of all medications are necessary steps. The susceptibility of PWE to contracting COVID-19 should be investigated further.

show abstract

“…Patients with COVID-19, particularly those with severe disease, experience neurologic manifestations with symptoms such as dizziness, headache, seizures, impaired consciousness, and acute cerebrovascular disease [ 12 , 75 , 76 ]. Central nervous system (CNS) complications are reported to manifest early in the course of infection [ 12 ].…”

Section: Main Textmentioning

confidence: 99%

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Brannagan

Auer‐Grumbach

Berk

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient’s preexisting comorbidities. Although COVID-19 primarily involves the respiratory system, dysfunction in multiple organ systems is common, particularly in the cardiovascular, gastrointestinal, immune, renal, and nervous systems. Patients with amyloid transthyretin (ATTR) amyloidosis represent a population particularly vulnerable to COVID-19 morbidity due to the multisystem nature of ATTR amyloidosis. Main body ATTR amyloidosis is a clinically heterogeneous progressive disease, resulting from the accumulation of amyloid fibrils in various organs and tissues. Amyloid deposition causes multisystem clinical manifestations, including cardiomyopathy and polyneuropathy, along with gastrointestinal symptoms and renal dysfunction. Given the potential for exacerbation of organ dysfunction, physicians note possible unique challenges in the management of patients with ATTR amyloidosis who develop multiorgan complications from COVID-19. While the interplay between COVID-19 and ATTR amyloidosis is still being evaluated, physicians should consider that the heightened susceptibility of patients with ATTR amyloidosis to multiorgan complications might increase their risk for poor outcomes with COVID-19. Conclusion Patients with ATTR amyloidosis are suspected to have a higher risk of morbidity and mortality due to age and underlying ATTR amyloidosis-related organ dysfunction. While further research is needed to characterize this risk and management implications, ATTR amyloidosis patients might require specialized management if they develop COVID-19. The risks of delaying diagnosis or interrupting treatment for patients with ATTR amyloidosis should be balanced with the risk of exposure in the health care setting. Both physicians and patients must adapt to a new construct for care during and possibly after the pandemic to ensure optimal health for patients with ATTR amyloidosis, minimizing treatment interruptions.

show abstract

Inpatient Neurology Consultations During the Onset of the SARS-CoV-2 New York City Pandemic: A Single Center Case Series

Cited by 22 publications

References 25 publications

Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19

Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19

COVID-19, de novo seizures, and epilepsy: a systematic review

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Contact Info

Product

Resources

About